Description of Collaborative Activity: |
This interagency working group (IWG) will help drive action in support of the Biden-Harris Administration goal of increasing access to evidence-based harm reduction services through expanded Medicaid reimbursement, comprehensive federal grant funding, research, and workforce training. Specifically, the IWG will focus on integrating harm reduction services with traditional health care infrastructure by developing sustainable funding streams needed to expand the availability of syringe services programs, naloxone, fentanyl test strips, and low-threshold medication treatment for opioid use disorder at harm reduction programs, as outlined in the 2022 National Drug Control Strategy. |
Type of Collaborative Activity: |
Committee, Advisory Group, or Work Group
|
HHS Agency Collaborators on this Activity: |
SAMHSA, ASPE, CMS, HRSA, CDC |
